Archaea: Microbial Candidates in Next-generation Probiotics Development : Journal of Clinical Gastroenterology

Secondary Logo

Journal Logo



Microbial Candidates in Next-generation Probiotics Development

Brugère, Jean-François PhD*; Ben Hania, Wajdi PhD*,†; Arnal, Marie-Edith PhD*; Ribière, Céline PhD; Ballet, Nathalie PhD§; Vandeckerkove, Pascal PhD§; Ollivier, Bernard PhD; O’Toole, Paul W. PhD

Author Information
Journal of Clinical Gastroenterology 52():p S71-S73, November/December 2018. | DOI: 10.1097/MCG.0000000000001043


Pharmabiotics and probiotics in current use or under development belong to 2 of 3 domains of life, Eukarya (eg, yeasts) and Bacteria (eg, lactobacilli). Archaea constitute a third domain of life, and are currently not used as probiotics, despite several interesting features. This includes the absence of known pathogens in humans, animals, or plants and the existence of some archaea closely associated to humans in various microbiomes. We promote the concept that some specific archaea that naturally thrive in the human gut are potential next-generation probiotics that can be rationally selected on the basis of their metabolic phenotype not being encountered in other human gut microbes, neither Bacteria nor Eukarya. The example of the possible bioremediation of the proatherogenic compound trimethylamine into methane by archaeal microbes is described.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid